Late-Breaking Science - International Stroke Conference 

The most anticipated studies of the year!

#ISC24 has the most highly-anticipated clinical trial breakthroughs and discoveries of the year! Join us in Phoenix, Arizona for results for RESILIENT- Extend; ZODIAC; MAGIC-MT Trial; EMBOLISE; STEM; Golden Bridge II; SELECT2; and so much more.

PLEASE NOTE: All Late-Breaking Science Main Event and Concurrent Abstract Sessions  are embargoed to the date and time of presentation.
All times are Mountain Standard Time (MST) (GMT -7)

Late-Breaking Science Main Event Sessions

Wednesday, February 7

Opening Main Event

Opening Main Event Schedule
Time Activity
11:50 a.m. ZODIAC - LB1. Zero Degree Head Positioning in Acute Large Vessel Ischemic Stroke
Anne Alexandrov, University of Tennessee Health Science Center, Memphis, TN
12:02 p.m. RESILIENT-Extend - LB2. Randomization of Endovascular Treatment with Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke due to Large VEssel OcclusioN Trial in the Extended Time Window
Raul Nogueira, University of Pittsburgh, Pittsburgh, PA
12:14 p.m. MOST- LB3. Multi-Arm Optimization of Stroke Thrombolysis Trial
Opeolu Adeoye, Washington University, Saint Louis, MO

Thursday, February 8

Thursday Main Event

Thursday Main Event Schedule
Time Activity
11:40 a.m. TREND - LB12. Intravenous Tirofiban Reduces Early Neurological Deterioration in Acute Ischemic Stroke: The Trend Randomized Controlled Clinical Trial
Zhao Wenbo, Xuanwu Hospital, Beijing, China
11:52 a.m. LB13. Uric Acid Supplementation Provides Cerebroprotection Across Different Animal Species, Sex, Age and Comorbidities: A Report From the Stroke Preclinical Assessment Network (SPAN)
Rakesh Patel, University of Iowa, Iowa City, IA
12:04 p.m. LB14. Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz: A Phase III Trial
Sun U. Kwon, Asan Medical Center, 138-736, Seoul, Korea, Republic of
12:16 p.m. Golden Bridge II - LB15. Effect of an Artificial Intelligence-Based Clinical Decision Support System on Stroke Care Quality and Outcomes in Patients With Acute Ischemic Stroke : A Cluster-Randomized Clinical Trial
Zixiao Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Friday, February 9

Closing Main Event

Closing Main Event Schedule
Time Activity
11:18 a.m. EMBOLISE: LB28. Embolization of the Middle Meningeal Artery With OnyxTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma
Jason Michael Davies, University at Buffalo, Buffalo, NY
11:30 a.m. MAGIC-MT: LB29. The MAGIC-MT Trial: Managing Non-Acute Subdural Hematoma Using Liquid Materials: A Chinese Randomized Trial of Middle Meningeal Artery Treatment
Ying Mao, Huashan Hospital, Fudan University, Shanghai, China
11:42 a.m. STOP-CAD: LB30. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Shadi Yaghi, Brown University, Providence, RI
11:54 a.m. STEM: LB31. STEM (The Squid Trial for the Embolization of the MMA for the treatment of CSDH)
Adam Arthur, Semmes-Murphey Neurological Clinic, Memphis, TN
12:06 p.m. LB32. Delayed Therapy With Humanized Anti-Sdc2 mAb Prevents Formation of Vasogenic Edema and Promotes Neuroprotection in Non-Human Primates With Ischemic Stroke
Federico Corti, Yale University, New Haven, CT
12:18 p.m. CHABLIS-II: LB33. Tenecteplase Thrombolysis for Stroke Up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial
Xin Cheng, Huashan Hospital Fudan University, Shanghai, China
12:30 p.m. LB34. Machine Learning Algorithms for Autonomous Detection of Stroke Symptoms and Bell's Palsy
Radoslav Raychev, UCLA, Los Angeles, CA
12:42 p.m. RAISE: LB35. Reteplase Treating Patients With Acute Ischemic Stroke (RAISE): A Phase 3, Multi-Centre, Open-Label, Randomised Controlled, Non-Inferiority Trial
Yongjun Wang, Beijing Tiantan Hospital, Fengtai District, Beijing, China
12:54 p.m. INSPIRES: LB36. Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke or Transient Ischemic Attack: The INSPIRES Randomized Clinical Trial
Yuesong Pan, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1:06 p.m. SELECT2: LB6. Long-Term Outcomes and EVT Treatment Effect From Randomized Controlled Trial of Endovascular Thrombectomy for Large Ischemic Strokes
Amrou Sarraj, University Hospital Cleveland Medical, Cleveland, OH

Late Breaking Science Concurrent Oral Abstract Sessions

Wednesday February 7

Late-Breaking Science Oral Abstracts I

Late-Breaking Science Oral Abstracts I
Time Activity
2:00 p.m. TESLA: LB4. The Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke Trial: 1-Year Outcome
Osama Zaidat, Mercy Health St. Vincent's Hospital, Toledo, OH
2:12 p.m. Twin2Win: LB5. A Randomized Study to Compare the Efficacy of Primary Dual-Stent Retriever vs. Primary Single-Stent Retriever Technique
Marc Ribo, Hospital Vall d Hebron, Barcelona, Spain
2:24 p.m. RESCUE: LB37. A Randomized, Blinded Placebo-controlled, Parallel Group Trial to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
Supurna Ghosh, Revalesio, Tacoma, WA
2:36 p.m. LB7. A Novel Artificial Intelligence Method to Measure Functional Outcomes in Rodents: A Report From the Stroke Preclinical Assessment Network (SPAN)
Mariia Kumskova, University of Iowa, Iowa City, IA

Late Breaking Science Oral Abstracts II

Late-Breaking Science Oral Abstracts II
Time Activity
4:45 p.m. LB8. Outcomes of Patients With Endovascular Thrombectomy in the Multi-Arm Optimization of Stroke Thrombolysis Trial
Colin Derdeyn, University of Iowa, Iowa City, IA
4:57 p.m. LB9. Subgroup Analysis of Fasudil Efficacy in the Multi-Laboratory Stroke Preclinical Assessment Network Trial
Takahiko Imai, Harvard Medical School, Massachusetts General Hospital, Boston, MA
5:09 p.m. LB10. Tenecteplase versus Alteplase for Acute Ischemic Stroke in the Oldest-Old Patients
Yunyun Xiong, Beijing Tiantan Hospital, Beijing, China
5:21 p.m. LB11. Fibrinogenase for Injection in the Treatment of Acute Ischemic Stroke: A Randomized Double Bline and Placebo Controlled Study
Xin Jiang, West China Hospital, Sichuan University, Chengdu, China

Thursday, February 8

Late Breaking Science Oral Abstracts III

Late-Breaking Science Oral Abstracts III
Time Activity
2:00 p.m. LB16. Infarct Size and Estimated Treatment Effect of Early versus Late Anticoagulation After Ischemic Stroke in People With Atrial Fibrillation
Urs Fischer, University Hospital Basel, Basel, Switzerland
2:12 p.m. ARCADIA: LB17. Anticoagulation for Prevention of Silent Infarct in the ARCADIA Trial
Maarten Lansberg, Stanford University, Palo Alto, CA
2:24 p.m. LB18. Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis Triggers Intracerebral Hemorrhage in Mutant KRAS-Induced Brain Arteriovenous Malformations
Hyejin Park, The University of Texas Health Science Center at Houston, Houston, TX
2:36 p.m. LB19. Secondary Analyses to Optimize Response to Andexanet from ANNEXa-1
Ashkan Shoamanesh, McMaster University/Population Health Research Institute, Hamilton, ON, Canada

Late Breaking Science Oral Abstracts IV

Late-Breaking Science Oral Abstracts IV
Time Activity
3:30 p.m. LB20. Lipid Accumulation in Mouse and Human Peripheral Blood Leukocytes After Ischemic Stroke and Its Correlation to Functional Outcome
Trang Do, UTHealth Houston- McGovern Medical, Houston, TX
3:42 p.m. LB21. Impact of Stenosis Degree on the Efficacy of Stenting versus Medical Therapy Alone for Symptomatic Intracranial Stenosis: A Preplanned Pooled Analysis of Individual Patient Data
Tao Wang, Xuanwu Hospital, Beijing, China
3:54 p.m. INSPIRES: LB22. Dual Antiplatelet Therapy in Patients With Multiple Acute Infarctions of Atherosclerotic Origin: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial
Yilong Wang, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
4:06 p.m. TIMELESS: LB23. Subgroup Analyses From the TIMELESS Trial
Gregory Albers, Stanford University, Palo Alto, CA

Late Breaking Science Oral Abstracts V

Late-Breaking Science Oral Abstracts V
Time Activity
4:45 p.m. LB24. Impact of COVID-19 Vaccine on Cerebrovascular Health: A Prospective Community-Based Study
Yiu ming bonaventure IP, The Chinese University of Hong Kong, Hong Kong, Hong Kong
4:57 p.m. ARCADIA: LB25. Atrial Cardiopathy Biomarkers and Atrial Fibrillation in the ARCADIA Trial
Hooman Kamel, Weill Cornell Medicine, New York, NY
5:09 p.m. LB26. Fingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network (SPAN)
Ligia Boisserand, Yale University, New Haven, CT
5:21 p.m. LB27. MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and First 900 Subjects
Steven Greenberg, MGH, Boston, MA

Helpful Hints

  • Trial results are prohibited from release until date and time of AHA designated embargo time. For Main Event and Concurrent Oral Abstract Late-Breaking Science the embargo time is the date and time of presentation at the International Stroke Conference 2024. Clinical trial sponsors must comply with embargo guidelines and policy established by the American Heart Association.

  • You are prohibited from sharing written embargoed information with anyone outside of the AHA with the exception of journal manuscript submission. Important Note: Industry announcements required by the SEC (Security Exchange Commission) must be approved by AHA prior to release and any level of information released without approval will be considered an embargo break.